Viking Therapeutics Inc. announced the completion of patient enrollment in its exploratory maintenance dosing clinical trial of VK2735 for obesity. VK2735 is a dual agonist of the GLP-1 and GIP receptors, being developed in both oral and subcutaneous formulations for the treatment of metabolic disorders such as obesity. The Phase 1 study is evaluating various maintenance dosing regimens—including subcutaneous and oral administration—following initial weight loss achieved with weekly VK2735 treatment. Approximately 180 adults with obesity have been enrolled. Results from this study are expected to be reported later this year. In addition, Viking is conducting two Phase 3 trials (VANQUISH-1 and VANQUISH-2) to assess the efficacy and safety of subcutaneous VK2735 in adults with obesity or overweight, with or without type 2 diabetes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58978) on January 08, 2026, and is solely responsible for the information contained therein.